## Strategy

## Who Are the Inflation Beneficiaries?

9 November 2020

## **Key Takeaway**

With COVID-19 uncertainties remaining, economic support and stimulus measures are still needed in many parts of the world, and a consequent rise in inflation-bias is possible at any time. At the same time, this inflation could coincide with accelerated consolidation, which changes the competitive landscape by giving pricing power to the dominant players. This report collects Jefferies Japan's research analysts' views on these topics.

Given the recent surge in COVID-19 infections in the EU and the US (and possibly in Japan), concerns are increasing. At the same time, governments are working on additional packages to support their economies. Together with easing monetary policy, sizable government fiscal support could create inflation-bias in the market, or could lead to actual inflation in Japan.

At the same time, consolidation is accelerating. The driving forces include: 1) calls for stronger corporate governance, leading to growth in acquisitions of, or divestiture and reshuffling of, subsidiaries; 2) COVID-19 acting as a trigger for industry consolidation. Often, these are industries where consolidation was needed to begin with, but COVID-19 has brought to the fore the necessity of consolidation, in order to survive and recover. In addition to the potential synergies created by consolidation, some players may gain pricing power, and these companies could thus stand to benefit from rising inflation.

Jefferies Japan analysts have been publishing reports on these themes, and this report collects our analysts' most recent views.

Hideyasu Ban \*
Equity Analyst
+81 36830 3611
hban@jefferies.com

Atul Goyal, CFA †
Equity Analyst
+65 6551 3965
agoyal@jefferies.com

Michael Jon Allen \*
Equity Analyst
+813 5251 6184
mallen3@jefferies.com

Mitsuko Miyasako \* Equity Analyst +813 5251 6176 mmiyasako@jefferies.com

Stephen Barker \*
Equity Analyst
+813 6830 3612
sbarker@jefferies.com

Masahiro Nakanomyo \*
Equity Analyst
+813 5251 6142
mnakanomyo@jefferies.com

Sho Fukuhara \*
Equity Analyst
+813 5251 6156
sfukuhara@jefferies.com

Hiroko Sato \*
Equity Analyst
+813 5251 6185
hsato@jefferies.com

Yoshihiro Azuma \* Equity Analyst +81 3 5251 6186 yazuma@jefferies.com

Thanh Ha Pham \*
Equity Analyst
+81 3 5251 6160
tpham@jefferies.com

William Montgomery, CFA \*
Equity Analyst
+813 6830 3614
wmontgomery@jefferies.com
^Prior trading day closing price unless
otherwise noted.

Please see analyst certifications, important disclosure information, and information regarding the status of non-US analysts on pages 20 to 25 of this report.



## **Table of Contents**

Chemicals/Electronic Components	
Consumer Electronics/Gaming/Telecoms	
Cosmetics and HPC	
Financial Services	
Healthcare/Med-Tech	
IT Services/Internet	
Machinery/Capital Goods	
Real Estate/J-REIT	
Retail	
Steel/Trading Houses/Energy	
Tech Precision / Semi Equipment	



# **Chemicals/Electronic Components**

Yoshihiro Azuma | yazuma@jefferies.com | +81-5251-6186

The companies that have consolidated or are consolidating in the sectors covered

In gas, recently, Nippon Sanso HD (4091 JP). Within the paint industry, consolidation is progressing gradually and steadily.

## How is consolidation impacting the pricing power of each player in the sector(s)?

In gas, players' pricing power is rising in the US and EU. In industrial gas, the four majors have 80% market share in the US and EU. The industrial gas industry has been consolidating. Linde acquired BOC in 2006, Air Liquide acquired Airgas in 2016, and Linde merged with Praxair in 2019. As a result, four companies (Linde, Air Liquide, Air Products, and Nippon Sanso) dominate the US and European markets. Industrial gas companies' pricing power has been rising for decades, and US gas suppliers have been successfully passing on raw material and logistics cost hikes. Decorative suppliers in India have strong pricing power, with Asian Paints as the price leader, while decorative paint suppliers in China do not, as it is still a fragmented market. Auto OEM paint suppliers have decent pricing power, with five suppliers (PPG, Axalta, BASF, Nippon Paint, and Kansai Paint) dominating the market.

#### Inflation beneficiaries

In an inflationary business environment, companies with 1) high financial leverage, 2) decent pricing power, 3) good enough execution capabilities (cost control), and 4) high breakeven points tend to outperform. Most Japanese diversified petrochemical companies (e.g., Mitsubishi Chemical and Mitsui Chemicals) meet criteria 1) and 4), but they do not have pricing power, and thus it would be tough for them to enjoy continuous margin expansion, unless there is really high inflation (such as a \$90–100/barrel oil price). We assume more-moderate inflation (a \$50–70 oil price). We believe Nippon Sanso meets criteria 1)–3) above. SUMCO, Kansai Paint, Taiyo Yuden, and Murata also meet the above criteria to a lesser degree.

## Financial leverage?

Niippon Sanso's net debt/EBITDA is 5x. Kansai Paint has almost zero.

In which sub-sector do you expect consolidation?

Paint: Yes

Gas: No

Sap: Yes

Wafer: No

Petro: No

Rubber: Yes (but marginal)

MLCC: No

Relevant report links

Nippon Sanso Top Pick in Inflationary Environment (23 October)

Nippon Sanso: Inflation + Debt = Equity Leverage (23 October)



# Consumer Electronics/Gaming/Telecoms

Atul Goyal, CFA | agoyal@jefferies.com | +65-6551-3965

Overall, we do not see material price inflation across the sectors we cover (telecoms, games, music/video subscription, electronic goods).

The companies that have consolidated or are consolidating in the sectors covered

- 1. Telecoms: Facing price cuts
- 2. Games: Prices are being raised from \$60 to \$70 after 14 years. This is just a delayed catch-up and barely covers the increase in development costs.
- Music/video subscription: The space remains pretty competitive—recently, Disney has offered monthly price plans of \$6-7, when Netflix was close to \$13-14.
- Electronic products: Apple offers much higher-spec (i.e., higher-value) products for the same prices. In essence, there is structural deflation in this space.

How is consolidation impacting the pricing power of each player in the sector(s)?

At best, the pace of price decline is becoming less steep.

Inflation beneficiaries

None

## **Cosmetics and HPC**

Mitsuko Miyasako | mmiyasako@jefferies.com | +81-3-5251-6176

How is consolidation impacting the pricing power of each player in the sector(s)?

Consolidation in the cosmetics and HPC sectors, if any, does not impact the pricing power of any particular player.

9 November 2020

## **Financial Services**

Hideyasu Ban | hban@jefferies.com | +81-3-6830-3611

#### The companies that have consolidated or are consolidating in the sectors covered

MUFJ Lease (8593 JP) and Hitachi Capital (8586 JP), within the MUFG Group (8306 JP). Shinsei Bank (8303 JP) announced that it would acquire 100% of the shares of its subsidiary, Aplus (8589 JP).

#### How is consolidation impacting the pricing power of each player in the sector(s)?

Consolidation within the leasing industry is not necessarily leading to a rise in pricing power since the market is still fragmented, but negotiating power in procuring leasing assets tends to be reinforced, which tends to lead to better profit margins and lower residual value risks.

Similarly, while banking sector consolidation will not lead to a rise in pricing power in the services they provide, the providers of systems and infrastructure to the regional banks for digitalization should benefit from regional bank consolidation.

On the other hand, consolidation of the domestic P+C insurance market is already done, but profitability is still relatively secured or improving, because of the oligopolistic nature of the market and also due to regulations.

#### Inflation beneficiaries

A steeper yield curve will benefit life insurers more than the other interest-rate-sensitive sectors given current monetary policy (yield curve control will tend to cap the rise in up to 10 year yields, the zone that is more beneficial to spread banking businesses).


At the same time, wholesale banking will benefit. Retail and wealth management business is already benefiting from the "stay home" environment (rises in trading volumes and new account openings). However, as inflation expectations rise, corporates will start accelerating investments, and investment (wholesale) banking business should benefit in such an environment

## Inflation and share price

Also, financial stock performance is more correlated with inflation expectations than the actual CPI. Banks and life insurers are the most highly-correlated and non-banks the least correlated.


Exhibits 1–4 show financial sub-sectors' performances relative to TOPIX versus the 10vear breakeven inflation rate

Exhibit 1 - BEI vs Banks (Relative to TOPIX)



Source: Jefferies, Bloomberg, FactSet

Exhibit 2 - BEI vs Insurance (Relative to TOPIX)




5

Source: Jefferies, Bloomberg, FactSet

9 November 2020

#### Exhibit 3 - BEI vs Brokers (relative to TOPIX)



Source: Jefferies, FactSet, Bloomberg

## In which sub-sector do you expect consolidation?

Major banks: No

Regional banks: Yes

Investment banks: No

Retail brokers: Yes


Leasing: Yes (continuing)

Consumer finance: Yes

P+C insurance: No

Life insurance: Yes

Exhibit 4 - BEI vs Non-Banks (Relative to TOPIX)



Source: Jefferies, Bloomberg, FactSet



## Healthcare/Med-Tech

Stephen Barker | sbarker@jefferies.com | +81-3-6830-3612

Naoya Miura | nmiura@jefferies.com | +81-3-6830-3613

How is consolidation impacting the pricing power of each player in the sector(s)?

Drug companies currently have pricing power that was not necessarily via consolidation in the US, and have historically been able to raise prices of on-patent drugs at a rate that exceeds inflation. However, this has invited political risk. One of the few things that both US parties agree on is the desirability of bringing down drug prices.

#### Inflation beneficiaries

We do not think any companies in the pharmaceutical, medical device, or biotech sectors are particularly likely to benefit from inflation. On the contrary, political risks in Japan and the US have led to ongoing pressure to lower drug prices.

As a result, we do not think investors will necessarily trust pharma companies to be a good hedge against inflation.

#### Financial leverage?

Most large-cap companies have little debt, so we think their financial risk is also minimal.

#### In which sub-sector do you expect consolidation?

Within pharma, there are two possible consolidation stories:

- Parent/child consolidation: Kirin may buy Kyowa Kirin and Sumitomo Chemical may buy Sumitomo Dainippon. This would not automatically give either company new pricing power, however.
- Generics: The two strongest local players, Sawai and Towa, may not actually buy any of their local competitors, and are very unlikely to merge. But these two companies may be able to continue to increase their market share as weak foreign and local players continue to get weaker.



## IT Services/Internet

Hiroko Sato | hsato@jefferies.com | +81-3-5251-6185

The companies that have consolidated or are consolidating in the sectors covered

IT services: SCSK bought and fully consolidated MINORI this year.

Internet: ZHD consolidated ZOZO, and next March will be fully consolidating LINE.

How is consolidation impacting the pricing power of each player in the sector(s)?

Internet: The merger of LINE and ZHD will form, at ¥3trn, Japan's biggest media platform. But will they have stronger pricing power as a result?

#### Inflation beneficiaries

IT services: There are many "must do" topics in this space that need to be addressed, such as DX, cashless, telework, etc. We do not think inflation (or deflation) will change IT spending much. Many of the investments happening now are to lower future IT spending costs.

Internet: There is currently a big shift towards on-line activity on the back of the coronavirus experience. We do not think Inflation will change that trend.

## Financial leverage?

Internet: Reasonably leveraged, but not overly so.

IT service companies: Basically most of the companies are cash-rich, low-leverage companies.

#### In which sub-sector do you expect consolidation?

IT service companies in general will likely see more consolidation as bigger companies are going after the engineering resources. Niche software solutions, consulting, datacenters, and service-oriented are targets for take-outs. DX-related, Cloud.

Internet: Digital content, logistics, financial-related services, cashless, DX-related, internet ad agencies, on-line doctors, on-line medical services, a variety of marketplace solutions.



# Machinery/Capital Goods

Sho Fukuhara | sfukuhara@jefferies.com | +81-3-5251-6156

Bolor Enkhbaatar, CFA | benkhbaatar@jefferies.com | +81-3-5251-6159

#### The companies that have consolidated or are consolidating in the sectors covered

Within the Japanese capital goods sector, companies that have been actively engaging in acquisitions include LIXIL Group (5938 JP), Nabtesco (6268 JP), Komatsu (6301 JP), Sumitomo Heavy Industries (6302 JP), Daikin Industries (6367 JP), Daifuku (6383 JP), Hoshizaki (6465 JP), and Hitachi (6501 JP). Mitsubishi Heavy Industries (7011 JP) conducts frequent internal consolidation as part of its restructuring activities. Japanese capital goods companies under our coverage have mostly secured top global share. Acquisitions usually help these companies expand their product line-up to penetrate new customer groups.

#### How is consolidation impacting the pricing power of each player in the sector(s)?

Companies' pricing power is not necessarily reinforced via consolidation, but we would highlight the following companies with strong pricing power in our universe. Daifuku's top presence in the global material handling industry has secured it the ability to offer value-added logistics solutions. Daikin executes a premium pricing policy in the global air-conditioning industry, especially in commercial air-conditioning. Komatsu faces intense price competition in China, but its pricing power remains high in other regions. Companies with high revenue exposure to the public and utilities sectors, such as Hitachi, would likely benefit from accelerating economic growth, with increased overall government and corporate spending.

## Inflation beneficiaries

Fiscal stimulus in Europe, Japan, and the US will likely lead to an inflationary environment. Under such a scenario, we highlight Daifuku, Daikin Industries, and Komatsu as the main beneficiaries among Japanese capital goods companies under our coverage. Our rationale rests on 1) these companies' pricing power in B-B (business-to-business) applications and leading market share, 2) a favorable pricing environment led by inflation, 3) accelerated pace of improving financial standing from better cash flow generation, and 4) ease of financing for acquisitions and organic growth.

## Financial leverage?

Most Japanese capital goods sector companies under our coverage have secured net cash positions. Mitsubishi Heavy Industries (7011 JP), Kawasaki Heavy Industries (7012 JP), and IHI (7013 JP) are the most leveraged within our coverage.

#### In which sub-sector do you expect consolidation?

Factory automation: No

Construction/agricultural machinery: No

Air conditioning: Yes

**Building equipment: No** 

-

Heavy industries: Yes

**Relevant report links** 

Who Will Benefit from an Inflationary Environment? (26 October)

9 November 2020



## Real Estate/J-REIT

William Montgomery, CFA | wmontgomery@jefferies.com | +81-3-6830-3614

#### The companies that have consolidated or are consolidating in the sectors covered

Office development by the nine largest Japanese developers has led them to increase market share of Tokyo office from 21.2% in 2014 to 24% in 2020. There has been very little M&A, although the takeover of Unizo in 2019/2020 and MBO of NTT Urban by parent NTT in 2018 stand out as examples. In particular, the final ¥6,000 take-out price of Unizo was 300% higher than the ¥2,000 market price before a bidding battle began.

In JREITs, there have been 19 mergers since 2010, including one successful hostile takeover in 2019. There have also been 23 IPOs of new JREITs since 2010, and they are rapidly increasing in variety. Logistics JREITs have been popular, and we cover three of them. We also cover two renewables infrastructure funds, similar to REITs.

## How is consolidation impacting the pricing power of each player in the sector(s)?

Given the commodity nature of real estate generally, this remains a challenge, but superior functionality, amenities, location, etc. of new development creates pricing power.

Consolidation of REITs is generally motivated more by cost benefits rather than pricing, but the larger the REIT, the larger the leasing network, and the easier it becomes to release properties.

#### Inflation beneficiaries

Exhibits 9–14 show Japanese OTC inflation-linked swap yields (FYISJY55 on Bloomberg)—a proxy for inflation expectations—against Mitsubishi Estate, Mitsui Fudosan, and the property market (TPREAL) share prices. These charts are frequently used to infer that, essentially, Japanese real estate stocks are "an inflation trade" and nothing much else. This oversimplifies fundamentals, but a strong relationship (93% correlation in 2013, 83% eight-year period) is compelling. A recent increase in inflation expectations to 0.102% (up 30bps in three months) has not been followed by an increase in developer share prices, which may be an opportunity (Exhibits 9–12).

In 2014, Abenomics led to the BOJ 2% targeted inflation rate (from the FYISJY55 charts we see expectations reached 1.5%). We can then see from exhibits 5 and 6 that real estate stock valuations (PBR) went up 2.5–3x. Any increasing risk of inflation makes these stocks attractive now, given distressed valuations near post-Lehman lows.

Exhibit 15 reveals that JGB yields and JREIT yields have directionally trended down together over time with lower interest rates, but suggests that during periods of crisis the risk component of cap rates overrides the price-of-money component.

Exhibit 17 explains the mechanisms of inflation in the property market. As suggested by Exhibit 16, both risk appetite and price-of-money factor into aggregate cap rates (discount rates).

#### Financial leverage?

Banks typically lend on a basis of close to 70% of project value, and over time IBD as a percentage of leasing assets, including inventory, tends to run around that level. Exhibit 7 shows Mitsui Fudosan (8801 JP) as an example. Mitsui's consolidated total leverage (IBD/total assets) is around 50%, with net debt/equity around 140%.

Most JREITs have leverage around 50%. NBF (8951 JP) is one of the longest-listed JREITs and maintains around 42% leverage (Exhibit 8).

#### In which sub-sector do you expect consolidation?

The Unizo takeover event led many to speculate that further M&A was possible in Japanese real estate given that many are trading below intrinsic value (Exhibits 5 and 6). As yet, this has not occurred but it remains a possibility.

We would expect consolidation of small and mid-sized JREITs. Many have proliferated during a bull market but are now trading at deep NAV discounts and are unable to grow.

#### Relevant report links

Japan Property Expert Survey: COVID-19 Impact (17 September)

Japanese Developers Stock Picking Guide (19 June)


Mitsubishi Estate - Becoming Significantly Undervalued (27 October)

Mitsui Fudosan - Also Significantly Undervalued (27 October)

Logistics J-REITS: Safety in Numbers (27 April)


Sunshine Is the Best Medicine: Initiate on Canadian Solar at Buy (30 September)

Exhibit 5 - Mitsui Fudosan (8801 JP) PBR




Source: Jefferies, Company data, Bloomberg

Exhibit 7 - Mitsui Fudosan (8801 JP) Leverage Employed




Source: Jefferies, Company data

Exhibit 6 - Mitsubishi Estate (8802 JP) PBR



Source: Jefferies, Company data, Bloomberg

Exhibit 8 - NBF (8951 JP) Leverage Employed



Source: Jefferies, Company data

**EQUITY RESEARCH**Japan | Equity Strategy

**Exhibit 9 - Mitsui Fudosan and Inflation Expectation** 



Source: Jefferies, Bloomberg

Exhibit 11 - Mitsui Fudosan Return vs. inflation Expectation



Inflation change vs. 3-mo forward return
 Linear (Inflation change vs. 3-mo forward return)

Source: Jefferies, Bloomberg

**Exhibit 13 - TPREAL and Inflation Expectation** 



Source: Jefferies, Bloomberg

**Exhibit 10 - Mitsubishi Estate and Inflation Expectation** 



Source: Jefferies, Bloomberg

Exhibit 12 - Mitsubishi Estate Return vs. iInflation Expectation




Inflation change vs. 3-mo forward return

Linear (Inflation change vs. 3-mo forward return)

Source: Jefferies, Bloomberg

**Exhibit 14 - TSEREIT Yield and Inflation Expectation** 



Source: Jefferies, Bloomberg

**EQUITY RESEARCH**Japan | Equity Strategy

## Exhibit 15 - 10-Year JGB and TSE REIT Average Yield

## Exhibit 16 - 10-Year JGB and Inflation Expectation



Source: Jefferies, Bloomberg

Source: Jefferies, Bloomberg


**EQUITY RESEARCH**Japan | Equity Strategy

Inflation impacts both the numerator and the denominator of the asset value equation.

The numerator (NOI) rises in an inflationary environment. Generally speaking, corporate earnings rise, which leads to increased property demand. NOI rises as a result.

The denominator (cap rates), while on the one hand are a function of interest rates (price of money) and liquidity (supply of money), are on the other hand a function of risk appetite, which generally increases in an inflationary environment.

#### Inflation impacts both the numerator Exhibit 17 - Asset Value = NOI/Cap Rate



Source: Jefferies



## Retail

#### Michael Allen | mallen3@jefferies.com | +81-3-5251-6184

Japanese retailing is usually the place that inflation goes to die. In most segments of the industry, there are hundreds of competitors offering roughly the same merchandise to highly informed consumers who are notoriously disloyal.

While we would argue that no company in our coverage has reliable pricing power, some would have more ability to deal with an inflationary environment than others. In general, most of the competitive advantages that some retailers enjoy would be the same regardless of the direction of general prices. However, there are at least three emerging fault-lines of competitive pressures that we see changing.

**Exhibit 18 - Pricing Power Factors** 

Tkr	Company	Core Segment	Estimated Share	No. of Competitors	Private Label (% of Sales)	Pricing
2651	Lawson	Food	4.0	270+	40	Centralized
2685	Adastria	Apparel	3.0	900+	50	Centralized
2782	Seria	Household Good:	30.0	4.0	30	Centralized
3034	QOL	Pharmacy	2.0	50000+	0	Centralized
3088	Matsumoto Kiyoshi	Drug Store	7.0	400+	13	Centralized
3141	Welcia	Drug Store	11.0	400+	5	Centralized
3349	Cosmos	Drug Store	10.0	400+	0	Decentralized
3382	7&i	Food	6.0	270+	45	Centralized
3391	Tsuruha	Drug Store	11.0	400+	8	Centralized
7453	Ryohin Keikaku	Home Fumisings	4.0	900+	100	Decentralized
7532	Pan Pacific	Discounter	2.0	270+	12	Decentralized
7606	United Arrows	Apparel	1.0	900+	50	Centralized
8227	Shimamura	Apparel	4.0	900+	30	Decentralized
9627	Ain	Pharmacy	3.5	50000+	0	Centralized
9843	Nitori	Furniture	13.0	2,210.0	n.a.	Centralized
9983	Fast	Apparel	11.0	900+	100	Centralized

Source: Company data

## **Store Level Pricing**

The newest line of competitive advantage that could change dramatically in the next several years is the ability to price goods at the local or store level. Most Japanese retailers are not set up to set prices at the store level. Companies that can do this, like Cosmos (3349 JP, Underperform) and Pan Pacific (7532 JP, Hold), are able to target local competitors for elimination by lowering prices locally without damaging their nationwide margins. This is not an easily-replicated skill. These companies not only have more-sophisticated software to set and track prices at the store level, but also have trained and incentivized hundreds of employees in how to gather raw market information and use it to set prices.

At least two other companies, Shimamura (8227 JP, Buy), and Ryohin Keikaku (7453 JP, Buy), are installing the necessary software and preparing to develop this capability. In both cases, management sees an opportunity to increase margins by cutting prices more carefully, if, when, and especially where necessary, without damaging margins in stores where the cuts are not needed. This strategy is designed to deal more effectively with deflationary pressures, but in our view, it should help in an inflationary environment equally well. The ability to hold prices down in locations that are more competitive, while raising prices selectively in less-competitive locations, should give these companies an advantage in an environment of rising prices as well.



#### **Private Label**

Historically, the primary differentiating factor in Japanese retailing was always real estate. With a declining population and the growth of e-commerce, superior location selection is no longer a viable path to leadership. Differentiation based on merchandise should become more important, but this skill-set is still in its infancy in Japan. Only two companies, Fast Retailing (9983 JP, Hold) and Ryohin Keikaku, rely on differentiated merchandise for 100% of their sales. Nitori (9843 JP, Hold) does not disclose the share of private label merchandise in its assortment, but its bid for Shimachu (8184 JP) includes a claim that private brands account for 90% of its revenue.

For most Japanese retailers, private label items are only a substitute for some other widely available commodity, and pricing power is more often lost because the retailer is now responsible for the inventory and must price the item to the level where it sells out.

Matsumoto Kiyoshi (3088 JP, Hold) is the most important exception to this rule, in our view. The company's merchandising developers are deeply involved in the development of new products that are not available elsewhere for the purpose of differentiating their brand. Matsumoto's share of the nationwide drugstore market is only about 8%. Its focus on cosmetics gives it a slightly higher edge of the cosmetics market, at probably 11%, and following a merger with Cocokarafine, we expect the share of the cosmetics market to rise to 19%. This expansion of market share should afford Matsumoto Kiyoshi an opportunity to further strengthen its private label assortment, but any pricing power the company achieves will be limited to its line of private label goods. Most of its merchandise will still be subject to intense pricing pressure.

#### **Mergers and Acquisitions**

Japanese retailers are no strangers to acquisitions. Of the 16 companies in our coverage, only two can claim to have relied on organic growth for 100% of their expansion, and eight consider M&A to be an essential component of their current strategy. Typically, however, an acquisition of a small company by a large one does not confer significant pricing power on the surviving entity, as the Japan Fair Trade Commission does not allow mergers that eliminate consumer choice in any local market. Only when merged entities subsequently develop a differentiated merchandising strategy can any pricing power be derived.

Mergers are typically more useful in helping to reduce the cost of advertising, distribution and procurement. Even if the merged entities cannot easily raise prices, they are often able to lower their costs. Most of the time, though, we cannot predict the timing or targets of such acquisitions, so counting on M&A for investment ideas is usually a difficult way to make money, in our view.



# Steel/Trading Houses/Energy

Thanh Ha Pham | tpham@jefferies.com | +81-3-5251-6160

Sangin Yun | syun@jefferies.com | +81-3-5251-6140

The companies that have consolidated or are consolidating in the sectors covered

Refiners—Oligopoly provides strong pricing power. Three refiners in Japan corner the refined oil products market. Recently ENEOS (5020 JP, Buy) merged with TonenGeneral in 2017, and Idemitsu Kosan (5019 JP, Buy) merged with Showa Shell 2019. The only independent refinery is Cosmo Energy (5021 JP, Hold). These three have tremendous pricing power in Japan. For example, despite plummeting Singapore margins, refinery spreads in Japan have been stable at around ¥10–11/liter. Thus, the domestic business is a cash cow. On top of this, due to ESG pressure, refiners are more conscious of shareholder returns and have pledged to pay out, on average, half of their earnings to shareholders. We think that this sector provides strong underlying fundamentals.


## How is consolidation impacting the pricing power of each player in the sector(s)?

Graphite electrodes have been consolidating in the last decade—Graftech (EAF) went bankrupt/was sold to a PE fund; SGL was sold to Tokai Carbon (5301 JP, Buy)/Showa Denko (4004 JP, Buy), and there was a hard close of 20% of capacity. Graphite electrodes are essential for producing steel in electric arc furnaces (EAFs). Recycling scrap steel is also experiencing a secular growth trend. Mini-mills are responsible for about 70% of steel production in the US, and about 45% in Europe. On the other hand, Asian steelmakers are still producing the bulk of their products via blast furnaces—melting iron ore with coking coal. However, a focus on the environment should boost the EAF ratio in the future, and demand for high-quality graphite electrodes should increase. Growing demand is meeting tight supply (limited capacity, and expanding production facilities is unlikely due to strict environmental controls). Thus, we expect price inflation for graphite electrodes as soon as H2 CY21. This would benefit major players, such as Tokai Carbon or Showa Denko.

Plant maintenance is a niche industry, as most plant owners have their own maintenance subsidiaries. Sankyu (9065 JP, Buy) and Raiznext (6379 JP, Buy) are the only independent and listed companies that provide maintenance service to large-scale plants. Excluding plant owners' subsidiaries, third-party maintenance (3PM) is a duopoly dominated by two companies. Continued increasing orders for Sankyu and Raiznext imply that plant owners do not have alternative maintenance service providers. Both Sankyu and Raiznext have been improving their profitability over the past few years, supported by increasing demand and a favorable competitive environment. Compared with EPC companies such as Chiyoda (6366 JP, Hold) or JGC (1963 JP), which usually target a GPM of 7–8%, plant maintenance companies already achieved GPM of more than 10%. Raiznext merged with JX Engineering, a 100% subsidiary of ENEOS, in July 2019, and we think there is a possibility that ENEOS may fully acquire Raiznext to procure enough resources for maintenance. Further consolidation would tighten industry supply/demand and benefit Sankyu, in our view.

**EQUITY RESEARCH**Japan | Equity Strategy

## **Exhibit 19 - Plant Maintenance Companies' GPM**



Source: Company data, Jefferies

## In which sub-sector do you expect consolidation?

Steelmakers: Yes

Trading companies: No

Oil refiners: No

Non-ferrous metal: No Plant engineering: Yes

Graphite electrode: No

Titanium: Yes

Road construction: Yes



# **Tech Precision / Semi Equipment**

Masahiro Nakanomyo | mnakanomyo@jefferies.com | +81-3-5251-6142

The companies that have consolidated or are consolidating in the sectors covered

Fujifilm is acquiring Hitachi's medical business. Fujifilm's Japan domestic market share in medical devices is now around 15%, and will go up to 20%.

#### Financial leverage?

Ricoh and Toshiba Tech's leverage are relatively high—their debt-to-equity ratios are above 200%.

In which sub-sector do you expect consolidation?

Printing: Yes

The printing market is maturing, and this trend is being accelerated by COVID-19. Tier-2 companies' earnings environments will be severe, and drastic change in profit structure will be needed.

SPF:Yes

The combined market share of the top-three companies in SPE is 70-80%. In the next stage, integration between different forms of equipment and expanding product portfolios will continue.

Analytical instruments: Yes

There are many small or mid-sized analytical instrument makers in Japan. These companies have specific products and technologies, but if they consolidate or are acquired by larger companies, there should be synergies.

Medical devices: Yes

Japanese medical companies are relatively small compared with the global competition. Integration and increasing corporate business domains will continue.

## **Relevant report links**

Office Equipment: Major Changes Coming-Initiate on Brother & Toshiba Tec (29 June)

**EQUITY RESEARCH**Japan | Equity Strategy

## **Analyst Certification:**

- I, Hideyasu Ban, certify that all of the views expressed in this research report accurately reflect my personal views about the subject security(ies) and subject company(ies). I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report.
- I, Atul Goyal, CFA, certify that all of the views expressed in this research report accurately reflect my personal views about the subject security(ies) and subject company(ies). I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report.
- I, Michael Jon Allen, certify that all of the views expressed in this research report accurately reflect my personal views about the subject security(ies) and subject company(ies). I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report.
- I, Mitsuko Miyasako, certify that all of the views expressed in this research report accurately reflect my personal views about the subject security(ies) and subject company(ies). I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report.
- I, Stephen Barker, certify that all of the views expressed in this research report accurately reflect my personal views about the subject security(ies) and subject company(ies). I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report.
- I, Masahiro Nakanomyo, certify that all of the views expressed in this research report accurately reflect my personal views about the subject security(ies) and subject company(ies). I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report.
- I, Sho Fukuhara, certify that all of the views expressed in this research report accurately reflect my personal views about the subject security(ies) and subject company(ies). I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report.
- I, Hiroko Sato, certify that all of the views expressed in this research report accurately reflect my personal views about the subject security(ies) and subject company(ies). I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report.
- I, Yoshihiro Azuma, certify that all of the views expressed in this research report accurately reflect my personal views about the subject security(ies) and subject company(ies). I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report.
- I, Thanh Ha Pham, certify that all of the views expressed in this research report accurately reflect my personal views about the subject security(ies) and subject company(ies). I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report.
- I, William Montgomery, CFA, certify that all of the views expressed in this research report accurately reflect my personal views about the subject security(ies) and subject company(ies). I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this research report.

**Registration of non-US analysts:** Hideyasu Ban is employed by Jefferies (Japan) Limited, a non-US affiliate of Jefferies LLC and is not registered/qualified as a research analyst with FINRA. This analyst(s) may not be an associated person of Jefferies LLC, a FINRA member firm, and therefore may not be subject to the FINRA Rule 2241 and restrictions on communications with a subject company, public appearances and trading securities held by a research analyst.

**Registration of non-US analysts:** Atul Goyal, CFA is employed by Jefferies Singapore Limited, a non-US affiliate of Jefferies LLC and is not registered/qualified as a research analyst with FINRA. This analyst(s) may not be an associated person of Jefferies LLC, a FINRA member firm, and therefore may not be subject to the FINRA Rule 2241 and restrictions on communications with a subject company, public appearances and trading securities held by a research analyst.

Registration of non-US analysts: Michael Jon Allen is employed by Jefferies (Japan) Limited, a non-US affiliate of Jefferies LLC and is not registered/qualified as a research analyst with FINRA. This analyst(s) may not be an associated person of Jefferies LLC, a FINRA member firm, and therefore may not be subject to the FINRA Rule 2241 and restrictions on communications with a subject company, public appearances and trading securities held by a research analyst.

**Registration of non-US analysts:** Mitsuko Miyasako is employed by Jefferies (Japan) Limited, a non-US affiliate of Jefferies LLC and is not registered/qualified as a research analyst with FINRA. This analyst(s) may not be an associated person of Jefferies LLC, a FINRA member firm, and therefore may not be subject to the FINRA Rule 2241 and restrictions on communications with a subject company, public appearances and trading securities held by a research analyst.

Registration of non-US analysts: Stephen Barker is employed by Jefferies (Japan) Limited, a non-US affiliate of Jefferies LLC and is not registered/qualified as a research analyst with FINRA. This analyst(s) may not be an associated person of Jefferies LLC, a

**EQUITY RESEARCH**Japan | Equity Strategy

FINRA member firm, and therefore may not be subject to the FINRA Rule 2241 and restrictions on communications with a subject company, public appearances and trading securities held by a research analyst.

**Registration of non-US analysts:** Masahiro Nakanomyo is employed by Jefferies (Japan) Limited, a non-US affiliate of Jefferies LLC and is not registered/qualified as a research analyst with FINRA. This analyst(s) may not be an associated person of Jefferies LLC, a FINRA member firm, and therefore may not be subject to the FINRA Rule 2241 and restrictions on communications with a subject company, public appearances and trading securities held by a research analyst.

Registration of non-US analysts: Sho Fukuhara is employed by Jefferies (Japan) Limited, a non-US affiliate of Jefferies LLC and is not registered/qualified as a research analyst with FINRA. This analyst(s) may not be an associated person of Jefferies LLC, a FINRA member firm, and therefore may not be subject to the FINRA Rule 2241 and restrictions on communications with a subject company, public appearances and trading securities held by a research analyst.

Registration of non-US analysts: Hiroko Sato is employed by Jefferies (Japan) Limited, a non-US affiliate of Jefferies LLC and is not registered/qualified as a research analyst with FINRA. This analyst(s) may not be an associated person of Jefferies LLC, a FINRA member firm, and therefore may not be subject to the FINRA Rule 2241 and restrictions on communications with a subject company, public appearances and trading securities held by a research analyst.

Registration of non-US analysts: Yoshihiro Azuma is employed by Jefferies (Japan) Limited, a non-US affiliate of Jefferies LLC and is not registered/qualified as a research analyst with FINRA. This analyst(s) may not be an associated person of Jefferies LLC, a FINRA member firm, and therefore may not be subject to the FINRA Rule 2241 and restrictions on communications with a subject company, public appearances and trading securities held by a research analyst.

Registration of non-US analysts: Thanh Ha Pham is employed by Jefferies (Japan) Limited, a non-US affiliate of Jefferies LLC and is not registered/qualified as a research analyst with FINRA. This analyst(s) may not be an associated person of Jefferies LLC, a FINRA member firm, and therefore may not be subject to the FINRA Rule 2241 and restrictions on communications with a subject company, public appearances and trading securities held by a research analyst.

Registration of non-US analysts: William Montgomery, CFA is employed by Jefferies (Japan) Limited, a non-US affiliate of Jefferies LLC and is not registered/qualified as a research analyst with FINRA. This analyst(s) may not be an associated person of Jefferies LLC, a FINRA member firm, and therefore may not be subject to the FINRA Rule 2241 and restrictions on communications with a subject company, public appearances and trading securities held by a research analyst.

As is the case with all Jefferies employees, the analyst(s) responsible for the coverage of the financial instruments discussed in this report receives compensation based in part on the overall performance of the firm, including investment banking income. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Aside from certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the analyst's judgement.

#### **Investment Recommendation Record**

(Article 3(1)e and Article 7 of MAR)

Recommendation Published November 9, 2020 , 05:18 ET.
Recommendation Distributed November 9, 2020 , 05:18 ET.

#### **Explanation of Jefferies Ratings**

Buy - Describes securities that we expect to provide a total return (price appreciation plus yield) of 15% or more within a 12-month period.

Hold - Describes securities that we expect to provide a total return (price appreciation plus yield) of plus 15% or minus 10% within a 12-month period.

Underperform - Describes securities that we expect to provide a total return (price appreciation plus yield) of minus 10% or less within a 12-month period.

The expected total return (price appreciation plus yield) for Buy rated securities with an average security price consistently below \$10 is 20% or more within a 12-month period as these companies are typically more volatile than the overall stock market. For Hold rated securities with an average security price consistently below \$10, the expected total return (price appreciation plus yield) is plus or minus 20% within a 12-month period. For Underperform rated securities with an average security price consistently below \$10, the expected total return (price appreciation plus yield) is minus 20% or less within a 12-month period.

NR - The investment rating and price target have been temporarily suspended. Such suspensions are in compliance with applicable regulations and/or Jefferies policies.

CS - Coverage Suspended. Jefferies has suspended coverage of this company.

NC - Not covered. Jefferies does not cover this company.

**EQUITY RESEARCH**Japan | Equity Strategy

Restricted - Describes issuers where, in conjunction with Jefferies engagement in certain transactions, company policy or applicable securities regulations prohibit certain types of communications, including investment recommendations.

Monitor - Describes securities whose company fundamentals and financials are being monitored, and for which no financial projections or opinions on the investment merits of the company are provided.

## Valuation Methodology

Jefferies' methodology for assigning ratings may include the following: market capitalization, maturity, growth/value, volatility and expected total return over the next 12 months. The price targets are based on several methodologies, which may include, but are not restricted to, analyses of market risk, growth rate, revenue stream, discounted cash flow (DCF), EBITDA, EPS, cash flow (CF), free cash flow (FCF), EV/EBITDA, P/E, PE/growth, P/CF, P/FCF, premium (discount)/average group EV/EBITDA, premium (discount)/average group P/E, sum of the parts, net asset value, dividend returns, and return on equity (ROE) over the next 12 months.

#### **Jefferies Franchise Picks**

Jefferies Franchise Picks include stock selections from among the best stock ideas from our equity analysts over a 12 month period. Stock selection is based on fundamental analysis and may take into account other factors such as analyst conviction, differentiated analysis, a favorable risk/reward ratio and investment themes that Jefferies analysts are recommending. Jefferies Franchise Picks will include only Buy rated stocks and the number can vary depending on analyst recommendations for inclusion. Stocks will be added as new opportunities arise and removed when the reason for inclusion changes, the stock has met its desired return, if it is no longer rated Buy and/or if it triggers a stop loss. Stocks having 120 day volatility in the bottom quartile of S&P stocks will continue to have a 15% stop loss, and the remainder will have a 20% stop. Franchise Picks are not intended to represent a recommended portfolio of stocks and is not sector based, but we may note where we believe a Pick falls within an investment style such as growth or value.

## Risks which may impede the achievement of our Price Target

This report was prepared for general circulation and does not provide investment recommendations specific to individual investors. As such, the financial instruments discussed in this report may not be suitable for all investors and investors must make their own investment decisions based upon their specific investment objectives and financial situation utilizing their own financial advisors as they deem necessary. Past performance of the financial instruments recommended in this report should not be taken as an indication or guarantee of future results. The price, value of, and income from, any of the financial instruments mentioned in this report can rise as well as fall and may be affected by changes in economic, financial and political factors. If a financial instrument is denominated in a currency other than the investor's home currency, a change in exchange rates may adversely affect the price of, value of, or income derived from the financial instrument described in this report. In addition, investors in securities such as ADRs, whose values are affected by the currency of the underlying security, effectively assume currency risk.

## **Distribution of Ratings**

Distribution of Ratings										
			IB Serv./Past12 Mos.		JIL Mkt Serv./Past12 Mos.					
	Count	Percent	Count	Percent	Count	Percent				
BUY	1500	58.09%	135	9.00%	12	0.80%				
HOLD	947	36.68%	23	2.43%	6	0.63%				
UNDERPERFORM	135	5.23%	1	0.74%	1	0.74%				

**EQUITY RESEARCH**Japan | Equity Strategy

#### **Other Important Disclosures**

Jefferies does business and seeks to do business with companies covered in its research reports, and expects to receive or intends to seek compensation for investment banking services among other activities from such companies. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Jefferies Equity Research refers to research reports produced by analysts employed by one of the following Jefferies Group LLC ("Jefferies") group companies:

**United States:** Jefferies LLC which is an SEC registered broker-dealer and a member of FINRA (and distributed by Jefferies Research Services, LLC, an SEC registered Investment Adviser, to clients paying separately for such research).

**United Kingdom:** Jefferies International Limited, which is authorized and regulated by the Financial Conduct Authority; registered in England and Wales No. 1978621; registered office: 100 Bishopsgate, London EC2N 4JL; telephone +44 (0)20 7029 8000; facsimile +44 (0)20 7029 8010.

**Hong Kong:** Jefferies Hong Kong Limited, which is licensed by the Securities and Futures Commission of Hong Kong with CE number ATS546; located at Suite 2201, 22nd Floor, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.

**Singapore:** Jefferies Singapore Limited, which is licensed by the Monetary Authority of Singapore; located at 80 Raffles Place #15-20, UOB Plaza 2, Singapore 048624, telephone: +65 6551 3950.

**Japan:** Jefferies (Japan) Limited, Tokyo Branch, which is a securities company registered by the Financial Services Agency of Japan and is a member of the Japan Securities Dealers Association; located at Tokyo Midtown Hibiya 30F Hibiya Mitsui Tower, 1-1-2 Yurakucho, Chiyoda-ku, Tokyo 100-0006; telephone +813 5251 6100; facsimile +813 5251 6101.

India: Jefferies India Private Limited (CIN - U74140MH2007PTC200509), licensed by the Securities and Exchange Board of India for: Stock Broker (NSE & BSE) INZ000243033, Research Analyst INH000000701 and Merchant Banker INM000011443, located at 42/43, 2 North Avenue, Maker Maxity, Bandra-Kurla Complex, Bandra (East), Mumbai 400 051, India; Tel +91 22 4356 6000.

**Australia:** Jefferies (Australia) Securities Pty Limited (ACN 610 977 074), which holds an Australian financial services license (AFSL 487263) and is located at Level 22, 60 Martin Place, Sydney NSW 2000; telephone +61 2 9364 2800.

This report was prepared by personnel who are associated with Jefferies (Jefferies International Limited, Jefferies Hong Kong Limited, Jefferies Singapore Limited, Jefferies (Japan) Limited, Tokyo Branch, Jefferies India Private Limited), Jefferies (Australia) Pty Ltd; or by personnel who are associated with both Jefferies LLC and Jefferies Research Services LLC ("JRS"). Jefferies LLC is a US registered broker-dealer and is affiliated with JRS, which is a US registered investment adviser. JRS does not create tailored or personalized research and all research provided by JRS is impersonal. If you are paying separately for this research, it is being provided to you by JRS. Otherwise, it is being provided by Jefferies LLC. Jefferies LLC, JRS, and their affiliates are collectively referred to below as "Jefferies". Jefferies may seek to do business with companies covered in this research report. As a result, investors should be aware that Jefferies may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only one of many factors in making their investment decisions. Specific conflict of interest and other disclosures that are required by FINRA and other rules are set forth in this disclosure section.

\* \* \*

If you are receiving this report from a non-US Jefferies entity, please note the following: Unless prohibited by the provisions of Regulation S of the U.S. Securities Act of 1933, as amended, this material is distributed in the United States by Jefferies LLC, which accepts responsibility for its contents in accordance with the provisions of Rule 15a-6 under the US Securities Exchange Act of 1934, as amended. Transactions by or on behalf of any US person may only be effected through Jefferies LLC. In the United Kingdom and European Economic Area this report is issued and/or approved for distribution by Jefferies International Limited ("JIL") and is intended for use only by persons who have, or have been assessed as having, suitable professional experience and expertise, or by persons to whom it can be otherwise lawfully distributed.

JIL allows its analysts to undertake private consultancy work. JIL's conflicts management policy sets out the arrangements JIL employs to manage any potential conflicts of interest that may arise as a result of such consultancy work. Jefferies LLC, JIL and their affiliates, may make a market or provide liquidity in the financial instruments referred to in this report; and where they do make a market, such activity is disclosed specifically in this report under "company specific disclosures".

For Canadian investors, this material is intended for use only by professional or institutional investors. None of the investments or investment services mentioned or described herein is available to other persons or to anyone in Canada who is not a "Designated Institution" as defined by the Securities Act (Ontario). In Singapore, Jefferies Singapore Limited ("JSL") is regulated by the Monetary Authority of Singapore. For investors in the Republic of Singapore, this material is provided by JSL pursuant to Regulation 32C of the Financial Advisers Regulations. The material contained in this document is intended solely for accredited, expert or institutional investors, as defined under the Securities and Futures Act (Cap. 289 of Singapore). If there are any matters arising from, or in

**EQUITY RESEARCH**Japan | Equity Strategy

connection with this material, please contact JSL, located at 80 Raffles Place #15-20, UOB Plaza 2, Singapore 048624, telephone: +65 6551 3950. In Japan, this material is issued and distributed by Jefferies (Japan) Limited to institutional investors only. In Hong Kong, this report is issued and approved by Jefferies Hong Kong Limited and is intended for use only by professional investors as defined in the Hong Kong Securities and Futures Ordinance and its subsidiary legislation. In the Republic of China (Taiwan), this report should not be distributed. The research in relation to this report is conducted outside the People's Republic of China ("PRC"). This report does not constitute an offer to sell or the solicitation of an offer to buy any securities in the PRC. PRC investors shall have the relevant qualifications to invest in such securities and shall be responsible for obtaining all relevant approvals, licenses, verifications and/or registrations from the relevant governmental authorities themselves. In India, this report is made available by Jefferies India Private Limited. In Australia, this report is issued and/or approved for distribution by, or on behalf of, Jefferies (Australia) Securities Pty Ltd. It is directed solely at wholesale clients within the meaning of the Corporations Act 2001 of Australia (the "Corporations Act"), in connection with their consideration of any investment or investment service that is the subject of this report. This report may contain general financial product advice. Where this report refers to a particular financial product, you should obtain a copy of the relevant product disclosure statement or offer document before making any decision in relation to the product. Recipients of this document in any other jurisdictions should inform themselves about and observe any applicable legal requirements in relation to the receipt of this document.

This report is not an offer or solicitation of an offer to buy or sell any security or derivative instrument, or to make any investment. Any opinion or estimate constitutes the preparer's best judgment as of the date of preparation, and is subject to change without notice. Jefferies assumes no obligation to maintain or update this report based on subsequent information and events. Jefferies, and their respective officers, directors, and employees, may have long or short positions in, or may buy or sell any of the securities, derivative instruments or other investments mentioned or described herein, either as agent or as principal for their own account. This material is provided solely for informational purposes and is not tailored to any recipient, and is not based on, and does not take into account, the particular investment objectives, portfolio holdings, strategy, financial situation, or needs of any recipient. As such, any advice or recommendation in this report may not be suitable for a particular recipient. Jefferies assumes recipients of this report are capable of evaluating the information contained herein and of exercising independent judgment. A recipient of this report should not make any investment decision without first considering whether any advice or recommendation in this report is suitable for the recipient based on the recipient's particular circumstances and, if appropriate or otherwise needed, seeking professional advice, including tax advice. Jefferies does not perform any suitability or other analysis to check whether an investment decision made by the recipient based on this report is consistent with a recipient's investment objectives, portfolio holdings, strategy, financial situation, or needs. By providing this report, neither JRS nor any other Jefferies entity accepts any authority, discretion, or control over the management of the recipient's assets. Any action taken by the recipient of this report, based on the information in the report, is at the recipient's sole judgment and risk. The recipient must perform his or her own independent review of any prospective investment. If the recipient uses the services of Jefferies LLC (or other affiliated broker-dealers), in connection with a purchase or sale of a security that is a subject of these materials, such broker-dealer may act as principal for its own accounts or as agent for another person. Only JRS is registered with the SEC as an investment adviser; and therefore neither Jefferies LLC nor any other Jefferies affiliate has any fiduciary duty in connection with distribution of these reports.

The price and value of the investments referred to herein and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

This report may contain forward looking statements that may be affected by inaccurate assumptions or by known or unknown risks, uncertainties, and other important factors. As a result, the actual results, events, performance or achievements of the financial product may be materially different from those expressed or implied in such statements.

This report has been prepared independently of any issuer of securities mentioned herein and not as agent of any issuer of securities. No Equity Research personnel have authority whatsoever to make any representations or warranty on behalf of the issuer(s). Any comments or statements made herein are those of the Jefferies entity producing this report and may differ from the views of other Jefferies entities.

This report may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor's. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party. Jefferies does not guarantee the accuracy, completeness, timeliness or availability of any information, including ratings, and is not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third-party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Neither Jefferies nor any third-party content provider shall be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses,

**EQUITY RESEARCH**Japan | Equity Strategy

legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase, hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice.

Jefferies research reports are disseminated and available electronically, and, in some cases, also in printed form. Electronic research is simultaneously made available to all clients. This report or any portion hereof may not be reprinted, sold or redistributed without the written consent of Jefferies. Neither Jefferies nor any of its respective directors, officers or employees, is responsible for guaranteeing the financial success of any investment, or accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this report or its contents. Nothing herein shall be construed to waive any liability Jefferies has under applicable U.S. federal or state securities laws.

For Important Disclosure information relating to JRS, please see https://adviserinfo.sec.gov/IAPD/Content/Common/crd\_iapd\_Brochure.aspx?BRCHR\_VRSN\_ID=483878 and https://adviserinfo.sec.gov/Firm/292142 or visit our website at https://javatar.bluematrix.com/sellside/Disclosures.action, or www.jefferies.com, or call 1.888.JEFFERIES.

© 2020 Jefferies Group LLC